Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2019 16:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update

Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 08, 2019 ...
August 07, 2019 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina

BASKING RIDGE, N.J. and MEMPHIS, Tenn., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development...
August 01, 2019 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Host 2019 Second Quarter Financial Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company...
July 15, 2019 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Receives Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia

BASKING RIDGE, N.J., July 15, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company...
June 04, 2019 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction

BASKING RIDGE, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company...
May 09, 2019 16:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update

All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively CLBS14-NORDA phase 3 program targeted to begin enrollment...
May 07, 2019 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Participate at the Upcoming May Conferences

BASKING RIDGE, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company...
May 02, 2019 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company...
April 03, 2019 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Participate in Upcoming Conferences

BASKING RIDGE, N.J., April 03, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company...
March 13, 2019 16:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company...